
Quarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Net Debt 2011-2026 | A
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.24 B | 918 M | 1.02 B | -448 M | -667 M | -377 M | -348 M | -266 M | 24 M | 11 M | -1.34 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.24 B | -1.34 B | -20.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Biodesix
BDSX
|
14.5 M | $ 15.7 | 4.18 % | $ 2.04 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.15 | -0.83 % | $ 4.94 M | ||
|
BioNano Genomics
BNGO
|
1.19 M | $ 1.16 | -3.33 % | $ 6.32 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 16.33 | 0.8 % | $ 176 M | ||
|
CareDx, Inc
CDNA
|
-39.2 M | $ 18.12 | -1.04 % | $ 966 M | ||
|
Celcuity
CELC
|
-28.1 M | $ 114.33 | 1.5 % | $ 5.35 B | ||
|
Aspira Women's Health
AWH
|
-512 K | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
-10.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 166.88 | -4.03 % | $ 8.27 B | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 25.0 | 0.64 % | $ 694 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Danaher Corporation
DHR
|
14 B | $ 191.23 | 0.06 % | $ 136 B | ||
|
DexCom
DXCM
|
-842 M | $ 63.01 | 1.26 % | $ 24.6 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 16.56 | -1.55 % | $ 501 M | ||
|
Guardant Health
GH
|
1.15 B | $ 90.84 | -3.19 % | $ 11.4 B | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 111.1 | -2.71 % | $ 9.16 B | ||
|
Interpace Biosciences
IDXG
|
-1.32 M | $ 1.92 | -1.92 % | $ 8.49 M | ||
|
Illumina
ILMN
|
-494 M | $ 126.95 | -0.34 % | $ 20.2 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
IQVIA Holdings
IQV
|
12 B | $ 169.58 | -2.12 % | $ 29.2 B | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 274.35 | 0.23 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
213 M | $ 75.67 | -0.57 % | $ 5.11 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 494.14 | -0.84 % | $ 14.3 B | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 256.28 | -0.29 % | $ 25.9 B | ||
|
Myriad Genetics
MYGN
|
115 M | $ 4.76 | 0.11 % | $ 441 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
ENDRA Life Sciences
NDRA
|
-270 K | $ 4.57 | -2.46 % | $ 3.6 M | ||
|
NeoGenomics
NEO
|
187 M | $ 7.98 | -0.25 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 9.51 | 1.01 % | $ 2.06 B | ||
|
National Research Corporation
NRC
|
71.3 M | $ 17.43 | 1.6 % | $ 390 M | ||
|
Natera
NTRA
|
-177 M | $ 204.77 | -1.54 % | $ 20.2 B | ||
|
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.41 | 5.05 % | $ 423 M | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 27.02 | -0.33 % | $ 20 B | ||
|
Precipio
PRPO
|
-2.19 M | $ 26.84 | 5.67 % | $ 43.1 M | ||
|
Personalis
PSNL
|
-48.8 M | $ 6.64 | 0.84 % | $ 393 M | ||
|
RadNet
RDNT
|
359 M | $ 55.13 | 0.62 % | $ 4.15 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M |